Moffitt logo

HURRICANE IAN UPDATE: Moffitt is open and working to reschedule patient appointments. Get the latest information.

Clinical Trials Search

Clinical Trial 21023

Cancer Type: Cutaneous
Study Type: Treatment
NCT#: NCT04812535

Phase: Phase II
Principal Investigator: Tarhini, Ahmad

Call 813-745-6100
or 1-800-679-0775 Learn More
Overview

Study Title

Open Label, Multicenter Phase II Study of the C5A- Antibody IFX-1 Alone or IFX-1 + Pembrolizumab in Patients with PD-1- or PD-L1-Resistant/Refractory Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC)

Summary

This is an open-label, non-randomized, Phase II study. Patients will be enrolled in 2 treatment arms (Arm A: IFX-1 monotherapy; Arm B: IFX-1 + pembrolizumab combination therapy).

Objective

- To assess the anti-tumor activity of IFX-1 - To determine the maximum tolerated dose or recommended Phase II dose

Treatments

Therapies

Immunotherapy; Therapy (NOS)

Medications

IFX-1 (); Not Applicable (); Pembrolizumab (Keytruda)

Inclusion Criteria

Inclusion Criteria:

  • At least 18 years of age on day of signing informed consent
  • Patients with biopsy-proven, histologically or cytologically confirmed (a.) locally advanced cSCC not amenable for curative treatment or (b.) metastatic cSCC. Patients must have been treated with all approved therapies for (a.) inoperable locally advanced cSCC contraindicated for radiation therapy or (b.) metastatic cSCC
  • Eastern Cooperative Oncology Group performance status (ECOG PS) status of ≤1
  • Patients must have progressed on treatment with an anti-PD-1/L1 monoclonal antibody (mAb) administered either as monotherapy or in combination with other checkpoint inhibitors or other therapies.
  • Patient provides written informed consent for the study
  • Other criteria apply

  • Exclusion Criteria

    Exclusion Criteria:

  • Patients with limited cSCC, who do not require systemic therapy
  • Has a diagnosis of immunodeficiency or autoimmune disease, or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 3 weeks prior the first dose of study treatment
  • Has severe hypersensitivity (Grade 3 or higher) to pembrolizumab or IFX-1 and/or any of their excipients or had a severe (Grade 3 or higher) infusion-related reaction to treatments with other mAbs
  • Patients who have undergone major surgery > Patients with known Grade 3 or higher (per National Cancer Institute common terminology criteria for adverse events [NCI CTCAE] v5.0 criteria) active systemic or cutaneous viral, bacterial, or fungal infection
  • Has known active central nervous system metastases and/or carcinomatous meningitis.
  • Patients with a history of other malignancies during the past 5 years
  • Patients with congestive heart failure, Class III or IV, by New York Heart Association criteria
  • Patients who are pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study,
  • Other criteria apply

  • If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.